SCHEMBL24254524

SCHEMBL24254524

Cc1ccc(S(=O)(=O)Nc2ccc(-n3ccnc3)cc2)cc1N

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.61
CYP2D6 P10635 1/20 0.61
PSEN1 P49768 1/20 0.61
PSEN2 P49810 1/20 0.61
APH1B Q8WW43 1/20 0.61
NCSTN Q92542 1/20 0.61
APH1A Q96BI3 1/20 0.61
PSENEN Q9NZ42 1/20 0.61
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
ALDH1A1 P00352 6/20 0.46
KDM4E B2RXH2 2/20 0.46
TERT O14746 1/20 0.46
MAPT P10636 8/20 0.45
LMNA P02545 3/20 0.45
CHRNA7 P36544 1/20 0.44
TNIK Q9UKE5 2/20 0.43
SCN9A Q15858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7129864 0.82 CYP3A4 (0.66) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL4880963 0.78 CYP3A4 (0.64) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL15646662 0.77 IDH2 (0.56) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL5318665 0.77 CYP3A4 (0.62) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL4883466 0.76 CYP3A4 (0.64) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL9761881 0.75 MAPT (0.50) ALDH1A1MAPTLMNAPKMMEN1
SCHEMBL11070041 0.75 KMT2A (0.60) CA12CA1CA2CA9ALDH1A1
SCHEMBL24254489 0.75 ALDH1A1 (0.61) ALDH1A1MAPTLMNAPKMMEN1
SCHEMBL24254493 0.72 CYP3A4 (0.50) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL24254525 0.72 CYP3A4 (0.50) CYP3A4CYP2D6PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 CYP3A4 3014/4885CYP2D6 3888/4885PSEN1 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.